Abstract
- Background
Over the past decade, the small polyphenolic compound resveratrol has garnered widespread scientific and public attention as a promising therapeutic and preventive agent for a broad spectrum of human chronic diseases. Extensive preclinical investigations utilizing purified enzymes, in vitro cell cultures, and laboratory animal models have consistently demonstrated that resveratrol possesses potent anti-aging, anti-carcinogenic, anti-inflammatory, and antioxidant properties. These multi-targeted biological activities suggest substantial translational potential for combating age-related pathologies and promoting human longevity. However, while preclinical evidence remains exceptionally robust, clinical investigations detailing the physiological responses to resveratrol supplementation in human subjects have only recently begun to emerge. Early human clinical trials primarily focused on establishing foundational pharmacokinetic profiles, systemic safety, and tolerability, establishing a clear consensus that resveratrol is generally well-tolerated by patients yet suffers from severely limited systemic bioavailability due to rapid and extensive phase-II metabolism. Consequently, relatively few published human studies have definitively confirmed whether the profound physiological benefits observed in laboratory models can be successfully replicated in clinical populations, though numerous advanced trials have been initiated. This comprehensive review aims to critically evaluate the current state of scientific knowledge regarding the physiological effects of resveratrol in humans and synthesize this data to establish robust, evidence-based guidelines for the design and implementation of future clinical trials.
- Methods
A systematic literature evaluation was performed across major scientific databases, focusing on peer-reviewed human clinical trials, pharmacokinetic analyses, and review articles examining oral resveratrol supplementation. Data extraction prioritized evaluating trial designs, participant demographics, dosing strategies, safety parameters, adverse event reporting, and systemic bioavailability metrics. Special emphasis was placed on identifying pharmacokinetic barriers—such as rapid glucuronidation and sulfation—and correlating systemic exposure levels with observed physiological endpoints in human cohorts. Furthermore, methodological frameworks from early-phase trials were analyzed to formulate optimized guidelines for upcoming clinical investigations.
- Results
Synthesized findings from published human clinical trials confirm that oral resveratrol supplementation possesses an excellent safety and tolerability profile across a broad range of administered dosages, with adverse events typically restricted to mild, transient gastrointestinal complaints at exceptionally high intake levels. However, pharmacokinetic evaluations consistently demonstrate that resveratrol exhibits poor systemic bioavailability, as parent compounds are rapidly metabolized into circulating glucuronide and sulfate conjugates. Despite these metabolic hurdles, emerging clinical trials investigating targeted physiological endpoints reveal promising modulations in inflammatory biomarkers, glycemic parameters, and vascular endothelial function. The review highlights that translating preclinical success into human efficacy requires overcoming pharmacokinetic limitations through innovative delivery systems, optimized dosing schedules, and carefully stratified patient cohorts.
- Conclusions
Resveratrol represents a compelling, multi-functional polyphenolic compound with significant translational potential in human health and chronic disease prevention. While early clinical trials establish its safety and underline significant pharmacokinetic challenges regarding bioavailability, the growing body of human data supports the execution of larger, methodologically rigorous clinical trials. Implementing the proposed guidelines for future trial design—focusing on enhanced formulations, appropriate biomarker tracking, and targeted patient populations—will be essential to conclusively validate resveratrol's therapeutic efficacy in clinical practice.
https://onlinelibrary.wiley.com/doi/10.1002/mnfr.201100143